News About

Lightning Round: CarMax, Asbury Automotive & More

Mon, 20 May 2013 18:43:03 -0400

Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

Dividend Highlights/Lowlights for May 20

Mon, 20 May 2013 17:04:24 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Agnico-Eagle Mines (AEM) – up 6% Apple Inc. (AAPL) – up 3% AllianceBernstein (AB) – up 3% Exxon Mobil (XOM) – up 1% Chevron Corporation (CVX) – up 1% Lowlights Amgen, Inc. (AMGN) – down [...]

NASDAQ 100 Round Up - Flat: FSLR, CTRP, BIDU

Mon, 20 May 2013 14:35:02 -0400

New York, May 20th (TradersHuddle.com) - The NASDAQ 100 Index is flat trading at 0, which represents 0% versus its previous close. The index is mixed for the session with slightly less than 50% of its components trading higher.

First Solar (NASDAQ:AMGN) closed the trading day at $105.63, near its 50 day moving average that is set at $103.20. Amgen's price action is just above this important support level, providing a trading opportunit. Read More --

Week in Review: RuiYi Signs Up Shanghai’s Genor to Develop mAb in China

Sat, 18 May 2013 06:27:00 -0400

RuiYi Inc., a San Diego-Shanghai biotech, signed an exclusive license with Genor BioPharma of Shanghai to develop RuiYi’s lead molecule in China; RuiYi also enlisted CMC Biologics to develop a cell line for RYI-008; Vectura, a UK maker of inhaled therapies, established a China respiratory JV with two partners: Tianjin KingYork and Zendex Bio Strategy; SciClone Pharma in-licensed China rights to a heart failure drug from Zensun (Shanghai) Science & Technology; WuXi PharmaTech released positive financial results and candidly discussed the performance of its business units; Amgen, which has not had a major presence in China, is now making good on its promise to use partnerships to establish itself; and BioDuro opened a new CRO laboratory in Shanghai, complementing its existing facility in Beijing. More details…..

Stock Symbols: (LSE: VEC) (NSDQ: SCLN) (NYSE: WX) (NSDQ: AMGN)

Share this with colleagues:

Amgen To Present At The UBS Global Life Sciences Conference

Thu, 16 May 2013 16:18:00 -0400

How to Play the Building Momentum in Amgen

Thu, 16 May 2013 07:20:03 -0400

New York, May 16th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the trading session at $107.42 with its price action in a very tight range, given that calculated support is set at $103.85 and the calculated resistance is set at $109.56. Read More --

Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment

Thu, 16 May 2013 07:00:00 -0400

New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Wed, 15 May 2013 18:02:00 -0400

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

Wed, 15 May 2013 18:00:00 -0400

Amgen-Zhejiang Beta China JV to Include R&D, Manufacturing

Wed, 15 May 2013 08:31:00 -0400

Last week, Amgen and Zhejiang Beta Pharma announced they would form a JV to bring Amgen’s biologic drugs to China, starting with Amgen’s colon cancer drug Vectibix. Now, an Amgen spokesperson told China Daily the JV will include a China-based R&D operation, along with manufacturing. Amgen has not been a big player in the PRC’s drug market, but details of the JV, as they emerge, show the company is making a serious commitment to China. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:

Should I Buy Pfizer? 3 Pros, 3 Cons

Wed, 15 May 2013 07:44:28 -0400

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Wed, 15 May 2013 04:13:17 -0400

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to

Trading Idea: Is Amgen close to Support?

Tue, 14 May 2013 07:40:04 -0400

New York, May 14th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading very close to calculated support at $103.85 with price action closing at just $106.89 and placing the stock near levels where traders will start paying attentio. Read More --

Amgen (AMGN) - Daily Volume Review

Tue, 14 May 2013 03:00:00 -0400

NEW YORK (AVAFIN) -- Options traders were heavily trading call contracts during the last ...

Amgen Is Close to the 50 Day Moving Average

Mon, 13 May 2013 09:12:03 -0400

New York, May 13th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $106.72, near its 50 day moving average that is set at $101.8461. Amgen's price action is just above this important support level, providing a trading opportun. Read More --

RBCC Partner n3D Signs U.S. Distribution Agreement

Mon, 13 May 2013 05:00:00 -0400

Strategy Behind Our Success, We Get in Early: PSX, AMGN, MPC and BAX

Sat, 11 May 2013 12:00:00 -0400

Short Interest in Vertex Rises, in Celgene Falls

Sat, 11 May 2013 10:45:31 -0400

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April.

The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ:

The Week in Review: Sagent Buys Out China JV Partner for $25 Million

Sat, 11 May 2013 03:16:00 -0400

Sagent Pharma, a US generic injectible drugmaker, will pay $25 million to acquire its partner’s 50% interest in a China manufacturing JV; ScinoPharm Taiwan and Coland Holdings formed a partnership to bring generic oncology drugs to mainland China; Zhejiang Huahai Pharma joined with Oncobiologics to develop and make biosimilars of four popular drugs; Hutchison Chi-Med will out-license global rights to a novel small-cell cancer drug this year; Zhejiang Beta Pharma and Amgen will form a JV to commercialize an Amgen cancer drug; Beijing Leadman Biochemistry will be the exclusive distributor in China for Immunodiagnostic Systems Holdings’ diagnostic tests; Teva Pharma, which does not have a substantial presence in China, considers its products a natural fit for China’s market; and Greg Scott, president of ChinaBio, pointed out that China partners are essential for western pharmas: “In China, unless you have deep resources, it is difficult to come and do everything yourself,” he said. More details….

Stock Symbols: (NSDQ: SGNT) (TSE: 1789) (TSE: 4144) (SHA: 600521) (AIM: HCM) (NSDQ: AMGN) (SHE: 300289) (NYSE: TEVA) (AIM: IDH)

Share this with colleagues:

Ex-Div Reminder for Amgen (AMGN)

Fri, 10 May 2013 10:34:21 -0400

On 5/14/13, Amgen Inc (AMGN) will trade ex-dividend, for its quarterly dividend of $0.47, payable on 6/7/13. As a percentage of AMGN's recent stock price of $104.54, this dividend works out to approximately 0.45%.

S&P Highlights Biotech ETFs

Fri, 10 May 2013 07:39:21 -0400

Bolstered by an accommodating Food & Drug Administration and promising recent clinical results for drugs aimed at treating conditions such as hepatitis C and multiple sclerosis, biotechnology stocks and ETFs have been stellar performers in 2013.

Recently, it was an announcement by Vertex (NASDAQ: VRTX) that its cystic fibrosis

Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China

Thu, 09 May 2013 16:14:39 -0400

Amgen (NASDAQ: AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver

Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China

Thu, 09 May 2013 16:08:00 -0400

Goal Is to Bring Amgen's Vectibix® (Panitumumab) to Chinese Patients

Technical Bull Stock Alert: Amgen, Inc. (AMGN), Target 112

Thu, 09 May 2013 11:17:40 -0400

Bridgewater, MA -- (SBWIRE) -- 05/09/2013 -- The online StockConsultant latest screen has found a biotechnology medicines company Amgen, Inc. (NASDAQ:AMGN) stock with a 75% bullish overall report and very good upside trade quality.

Bull’s Eye Report: Amgen (AMGN)

Thu, 09 May 2013 08:33:19 -0400

How To Profit From The Next Wave Of Dividends

Thu, 09 May 2013 08:00:52 -0400

Zhejiang Beta Pharma Forms JV with Amgen

Thu, 09 May 2013 07:16:00 -0400

Zhejiang Beta Pharma and Amgen will form a joint venture to commercialize Amgen's Vectibix^® (panitumumab) in China. Vectibix is a treatment for colorectal cancer. In addition to being experienced with targeted therapies, Zhejiang Beta also has a well-established China oncology sales network. The JV will be 51% owned by Zhejiang Beta, with Amgen holding the remainder. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:

Closing Bell for Wednesday on Wall Street: Markets Open Lower, Stock Prices Rise All Day

Wed, 08 May 2013 12:05:00 -0400

DailyFinance.com: U.S. equity markets opened lower this morning on relatively little economic data. In Europe, Germany reported that industrial production rose 1.2%, while a house price index in the U.K.rose 1.1% month-over-month. In Asia, China reported a ... Read more

Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Perrigo Co. (NASDAQ:PRGO), and Amgen Inc. (NASDAQ:AMGN) Added to Growing Stock Report's NASDAQ Decliners Watch List.

Wed, 08 May 2013 08:33:55 -0400

New York, NY -- (SBWIRE) -- 05/08/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Perrigo Co. (NASDAQ:PRGO), and Amgen Inc. (NASDAQ:AMGN).

Amgen Is Close to its 50 Day Moving Average

Wed, 08 May 2013 08:04:02 -0400

New York, May 8th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $104.46, near its 50 day moving average that is set at $100.96. Amgen's price action is just above this important support level, providing a trading opportunity. Read More --

Amgen Announces Top-Line Results of Vectibix Phase 3 Head-to-Head Study Against Erbitux in Metastatic Colorectal Cancer

Tue, 07 May 2013 16:06:53 -0400

Amgen (NASDAQ: AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival.

Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer

Tue, 07 May 2013 16:04:00 -0400

Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting

Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Perrigo Co. (NASDAQ:PRGO), and Amgen Inc. (NASDAQ:AMGN) Added to Equity Profile Report's NASDAQ Decliners Watch List.

Tue, 07 May 2013 15:53:40 -0400

Wilmington, DE -- (SBWIRE) -- 05/07/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Perrigo Co. (NASDAQ:PRGO), and Amgen Inc. (NASDAQ:AMGN).

Florida Won't Protect Biotechs From Competition

Tue, 07 May 2013 13:13:46 -0400

X Factor: 5 Stocks Reaching Their Ex-Dividend Date on May 14

Tue, 07 May 2013 10:07:00 -0400

Microsoft, Archer Daniels Midland Company, and Marathon Oil Corporation are on the list.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Amgen Inc. (NASDAQ:AMGN) Added to Growing Stock Report's NASDAQ Decliners Watch List.

Tue, 07 May 2013 09:02:09 -0400

New York, NY -- (SBWIRE) -- 05/07/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Amgen Inc. (NASDAQ:AMGN).

Amgen is Near a Key Support Area

Tue, 07 May 2013 08:12:02 -0400

New York, May 7th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) finished near calculated support at $103.85.

The biotechnology company closed at $104.83 leaving shares at a level that will spark interest by traders wanting to start or. Read More --

NASDAQ Decliners Watch List: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Amgen Inc. (NASDAQ:AMGN) Added to Equity Profile Report's NASDAQ Decliners Watch List.

Mon, 06 May 2013 16:33:56 -0400

Wilmington, DE -- (SBWIRE) -- 05/06/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Amgen Inc. (NASDAQ:AMGN).

IBB, AMGN, CELG, ALXN: ETF Inflow Alert

Mon, 06 May 2013 11:06:44 -0400

Symbols mentioned in this story: IBB, AMGN, CELG, ALXN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.

Amgen Has Returned 17.4% Since SmarTrend Recommendation (AMGN)

Mon, 06 May 2013 10:48:00 -0400

Amgen (AMGN), Transgenomic Enter CE-IVD Test Development Agreement

Mon, 06 May 2013 07:14:41 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8306214 for the full story.

Transgenomic in Collaboration Agreement with Amgen

Mon, 06 May 2013 07:07:33 -0400

Transgenomic, Inc. (OTC: TBIO) today announced that it has entered into a collaboration with Amgen Inc. (NASDAQ: AMGN) to develop a CE-IVD test to screen patients with metastatic colorectal cancer

Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Patients with Metastatic Colorectal Cancer

Mon, 06 May 2013 07:00:00 -0400

World’s Premiere Science Journal Touts Revolutionary Innovations by RBCC Partner Nano3D

Mon, 06 May 2013 05:00:00 -0400

UPDATE: Monkeys Treated with Amgen (AMGN) Drugs More Likely to Survive Nuclear Attack; FDA Approves Use

Fri, 03 May 2013 15:55:12 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8304464 for the full story.

Best Investments 2013: This Could Be the Most Lucrative Time Ever for Biotech

Fri, 03 May 2013 12:40:45 -0400

Some of the most exciting developments in the last fifty years have been in the biotechnology industry - which has also meant the emergence of some of the best investments for 2013.

Just look at the progress biotech has made in medicine.

Using advanced technology and research, scientists in the life sciences industry are working on cures for diseases that have plagued mankind for decades. In a relatively short period of time, biotechnology has produced medications that have pushed many forms of cancer to the brink of defeat. HIV infection went from a death sentence to a manageable - and almost cured - condition, in just a few decades.

Biotech share prices have reflected these successes.

As Barron's pointed out last week, biotech stocks have soared 111% over the past couple years, about three times better than healthcare stocks.

And early investors in biotech have seen astronomical gains over the past four to five years.

Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) has soared from less than $5 a share back in 2005 to more than $240 a share today as its drugs have been used to battle ophthalmological disease and several forms of cancer. Incyte Corp. (Nasdaq: INCY) has seen its stock price rise from $2 a share just four years ago to more than $20 today. Early investors in industry leader Amgen Inc. (Nasdaq: AMGN) have seen gains of almost 100 times their initial investment.

But those gains are far from over.

In fact, right now just may be the best time in history to be an investor in the biotechnology sector.

To continue reading, please click here…

Big drugmakers think small with nanomedicine deals

Fri, 03 May 2013 06:03:29 -0400

* Early-stage research but scientists see momentum building

UPDATE 2-Gilead profit rises, but sales of older HIV drugs dip

Thu, 02 May 2013 18:28:26 -0400

May 2 (Reuters) - Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.

Top Fund Buys Focus On Defensive Stocks, Housing

Thu, 02 May 2013 17:45:00 -0400

April notched another month of gains for the stock market. That's four straight months so far this year. But this market rally is getting long in the tooth and top fund managers have been cautious in their buying. The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firms Celgene (CELG), Biogen Idec (BIIB) and Amgen (AMGN) and Regeneron Pharmaceuticals (REGN), in their